KFDA approves pazopanib for kidney cancer

Published: 2010-08-23 06:58:00

Updated: 2010-08-23 06:58:00

The Korea Food and Drug Administration said on August 11 it has approved Pazopanib tablets (Votrient, GlaxoSmithKline) for the treatment of patients with advanced renal cell carcinoma.

Pazotinib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VE...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK